Reconsidering the drug discovery pipeline for designed multitarget drugs

Drug Discovery Today

Volumn 18, Issue 23-24, 2013, Pages 1129-1130

  Proschak, Ewgenij ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DESIGNED MULTITARGET LIGAND; DRUG; UNCLASSIFIED DRUG;

CHRONIC INFLAMMATION; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; EDITORIAL; EXPERIMENTAL ANIMAL; GENE SILENCING; HUMAN IMMUNODEFICIENCY VIRUS; MALIGNANT NEOPLASTIC DISEASE; METABOLIC SYNDROME X; NONHUMAN; PHARMACODYNAMICS; PHENOTYPE; VIRUS INFECTION; ANIMAL; HUMAN; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANIMALS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84889102562     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.08.019     Document Type: Editorial

References (9)

1. R. Morphy, and Z. Rankovic The physicochemical challenges of designing multiple ligands J. Med. Chem. 49 2006 4961 4970
2. L. Costantino, and D. Barlocco Designed multiple ligands: basic research vs clinical outcomes Curr. Med. Chem. 19 2012 3353 3387
3. A.L. Hopkins Network pharmacology: the next paradigm in drug discovery Nat. Chem. Biol. 4 2008 682 690
4. A.C. Dar Chemical genetic discovery of targets and anti-targets for cancer polypharmacology Nature 486 2012 80 84
5. X. Tan Systematic identification of synergistic drug pairs targeting HIV Nat. Biotechnol. 30 2012 1125 1130
6. J.L. Medina-Franco Shifting from the single to the multitarget paradigm in drug discovery Drug Discov. Today 18 2013 495 501
7. R. Morphy, and Z. Rankovic Fragments, network biology and designing multiple ligands Drug Discov. Today 12 2007 156 160 2007
8. G. Bottegoni The role of fragment-based and computational methods in polypharmacology Drug Discov. Today 17 2012 23 34
9. J. Besnard Automated design of ligands to polypharmacological profiles Nature 492 2012 215 220